Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively Smoking Family Members
The purpose of this pilot study is to examine, in an innovative setting, the potential for a lung cancer diagnosis in a loved one to represent a teachable moment for smoking cessation in family members or caregivers who are current smokers. The researchers will identify the willingness and preferred modality for smoking cessation among family members/caregivers in this setting. The researchers will estimate abstinence rates at 4, 8, 12, and 24 weeks..
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 18, 2024 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Indiana University
- Interventions being studied
- Behavioral: Digital-based support; Behavioral: Traditional-based support + Nicotine replacement therapy (NRT)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
Patient 1. patient with newly diagnosed lung cancer within the last 6 months of initial diagnosis/confirmation of diagnosis at the study sites 2. Able to provide informed consent 3. Able to speak and read English Family Member/Caregiver Participant Criteria: 1. Family member or caregiver (defined as first degree relative \[parent, sibling, child\] or person living in the same household) 2. Family member or caregiver must be a current, active smoker (defined as 10 cigarettes per day for 6 consecutive months). 3. At least 18 years of age at time of study consent 4. Able to provide informed consent 5. Able to speak and read English
1. Currently receiving formal tobacco dependence treatment- Nicotine replacement of any kind, varenicycline or Bupropion. 2. Medical condition that precludes proposed pharmacotherapy for smoking cessation : Recent (≤ 2 weeks) myocardial infarction , history of underlying arrhythmias , history of serious or worsening angina pectoris, pregnancy and breastfeeding
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Indiana University Melvin & Bren Simon Cancer CenterIndianapolis, Indiana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 18, 2024. Always confirm current availability with the study team.